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Summary Cardiologists and physicians have witnessed a signiﬁcant change in the manage-
ment of atrial ﬁbrillation (AF): antiarrhythmic agents are no longer considered more effective
than just merely using compounds that control ventricular response of the arrhythmia with
anticoagulation in high-risk patients. Catheter ablation has grown into wider acceptance as an
important therapeutic modality in treating tachyarrhythmias. And over the past decade, several
studies have clearly established that catheter ablation of atrial ﬁbrillation is safe and effective
and is an important alternative therapeutic option to the pharmacological approach.
In general, there are two approaches to AF ablation: The anatomical approach, the most
popular one, relies on isolation of electrical connections of all four pulmonary veins to the left
atrium with or without adjuvant ablations, i.e. additional linear ablations. The second approach
is the electrogram-guided approach by mapping and targeting areas of complex fractionated
atrial electrograms (CFAE) which is the main topic of this review.
The myriad pathologies leading to and resulting from AF have led to many theories regarding
how substrate should be deﬁned and how to reconcile substrate ablation with trigger ablation.
The identiﬁcation of spatiotemporally stable areas of very low amplitude short cycle length CFAE
in a sea of otherwise discrete normal amplitude and relatively longer cycle length electrograms
led to ablate the CFAE as a marker of abnormal substrate. This pure substrate-based abla-
tion strategy has resulted in remarkable success, including mortality beneﬁt, even in high-risk
patients with very long standing persistent AF. In this review, we discuss in detail the prevailing
mechanisms underlying CFAE, how to map and ablate CFAE sites, correlation of CFAE areas to
those of ganglionic plexi, clinica utcomes of the approach, and the role of CFAE in the hybrid
approach of AF ablation using a
areas.
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ntroduction
t has been just about 15-year anniversary of the ﬁrst seri-
us attempt to perform catheter ablation to cure atrial
brillation (AF) [1]. Shortly after Swartz et al. introduced
he catheter-based Maze procedure [1], Haissaguerre and
olleagues published a landmark paper revealing that the
ulmonary veins (PVs) are an important source of triggering
oci for paroxysmal AF [2]. This discovery caused elec-
rophysiologists to focus on PVs as important target sites
or AF ablation, marking a new era in the treatment of
F.
Antiarrhythmic drugs were the mainstay of AF man-
gement for a long time—–until two key studies, AFFIRM
3] and RAFT [4], demonstrated that the strategy of
aintaining sinus rhythm with antiarrhythmics was not
etter than that of rate control by a -blocker or
alcium-channel blocker in conjunction with anticoagula-
ion. This observation inevitably disappointed clinicians
nd prompted researchers to look for an alterna-
ive way to treat AF patients. Thus, the develop-
ent of catheter ablation emerged at an auspicious
ime.
Catheter ablation for AF is constantly evolving even
oday. The initial ablative approach was to focally ablate
he culprit PV identiﬁed as the triggering site initiating
F [2,5]. This approach was quickly abandoned because
t was time consuming and had a relatively low success
ate. Electrophysiologists then began to isolate the electri-
al connections of all four veins from the left atrial (LA)
uscle.
Various techniques were utilized to achieve electrical iso-
ation of the PVs (PVI) including: (1) segmental isolation
ntroduced by Haissaguerre and colleagues [6]; (2) PVI at
he antrum of the PVs at the atrium—venous junction using
Current approaches for atrial ﬁbrillation
ablation techniques
A recent consensus of world-renowned experts in AF abla-
tion states that PVI is a cornerstone of catheter ablation
of the AF, and most laboratories perform PVI as the pri-
mary approach for patients with paroxysmal AF [9]. Its
success rate in the paroxysmal AF subset ranges from 38 to
70% after a single procedure and 65 to 90% after repeated
procedures.
However, PVI alone is not effective for treating patients
with persistent AF [9]. As a result, there is a strong trend
to add ablation lines in the LA and ablate in the coronary
sinus and the right atrium (RA) over and above traditional
PVI. These developments demonstrate the importance of
AF substrate ablations, which should be an integral part of
successful ablation strategies.
Logically, the best approach to identify target sites of
AF ablation would be to ﬁnd substrates that perpetuate the
arrhythmia. In the past, it was believed that AF substrates
cannot be mapped because reentrant circuits underlying the
substrate are random and not amendable for point-to-point
or endocardial mapping. However, our recent observational
studies have demonstrated that substrates serving as ‘‘AF
perpetuators’’ can be identiﬁed by searching for areas that
have complex fractionated atrial electrograms (CFAEs) [10].
During sustained AF, CFAEs are often recorded in speciﬁc
areas of the atria, and exhibit temporal and spatial sta-
bility [10—12]. By ablating areas that have persistent CFAE
recording, our studies showed that AF was terminated in
over 85% of patients, and more importantly, the procedure
yielded a very good long-term outcome in both paroxysmal
and chronic AF patients [10,13].
Hence, current ablation techniques include the follow-
ing two approaches: (1) the anatomical approach with PVI;ntracardiac ultrasound guidance [7] or electroanatomical
apping; and (3) circumferential PV ablation popularized
y Pappone et al. [8]. To avoid PV stenosis, more investiga-
ors now perform PVI further away from the PV ostia, making
ider areas of ablation in the LA.
o
t
w
t
er (2) the electrogram (CFAE)-guided approach. At present,
he anatomical approach is most commonly employed world-
ide, whereas the electrogram-guided approach is conﬁned
o a few laboratories. Since there have been numerous
xcellent reviews of catheter ablation of AF using the
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wFigure 1 Complex fractionated atrial electrograms are comp
baseline with continuous deﬂections from a prolonged activation
CS, coronary sinus; LA, left atrium; LIPV, left inferior pulmonar
anatomical approach, this review will focus only on the
electrogram-guided approach.
Characteristics of atrial electrograms during
atrial ﬁbrillation
Over the past decade, several important observations were
made during mapping studies in human AF. First, atrial elec-
trograms during sustained AF have three distinct patterns:
single potential, double potential, and complex fractionated
potential (CFAEs) [13—15]. Second, during AF, these atrial
electrograms tend to localize in speciﬁc areas of the atria
and do not meander, exhibiting surprisingly remarkable tem-
poral and spatial stability [11,12,16]. Third, the CFAE areas
represent the AF substrate sites, which have become impor-
tant target sites for AF ablation [10,17,18]. By ablating such
areas that have a persistent CFAE recording, one eliminates
AF and usually renders AF non-inducible. Thus, CFAE map-
ping has become a novel approach for guiding a successful
ablation of AF substrate, yielding excellent long-term out-
comes.
CFAEs are deﬁned as low voltage atrial electrograms
(ranging from 0.04 to 0.25mV) that have fractionated elec-
trograms composed of two deﬂections or more, and/or have
a perturbation of the baseline with continuous deﬂection of
a prolonged activation complex. CFAE have a very short cycle
length (≤120ms) with or without multiple potentials; how-
ever, when compared to the rest of the atria, this site has
the shortest cycle length (Fig. 1).
Electrophysiologic mechanisms underlying
CFAEs
The underlying etiology of CFAE has not yet been elucidated,
but several theories are being investigated. Pioneering work
by Wells et al. [15] identiﬁed four types of atrial electro-
b
t
e
e
rof two deﬂections or more and/or have a perturbation of the
plex; or are associated with a very short cycle length (≤120ms).
n; RSPV, right superior pulmonary vein.
rams that may be present in AF:
Type I: Discrete complexes separated by an isoelectric
baseline free of perturbation.
Type II: Discrete complexes, but with perturbations of the
baseline between complexes.
Type III: Fractionated electrograms that fail to demon-
strate either discrete complexes or isoelectric intervals.
Type IV: Electrograms of Type III alternating with periods
characteristic of Type I and/or Type II electrograms.
Konings et al. [14] applied this knowledge during intra-
perative studies and identiﬁed three types of AF based on
heir mechanism of propagation:
Type I: Single broad-wave fronts propagating without sig-
niﬁcant conduction delay, exhibiting only short arcs of
conduction block or small areas of slow conduction not
disturbing the main course of propagation.
Type II: Activation patterns characterized either by single
waves associated with a considerable amount of conduc-
tion block and/or slow conduction or the presence of two
wavelets.
Type III: Presence of three or more wavelets associated
with areas of slow conduction (10 cm/s) and multiple arcs
of conduction block.
alifa et al. [19] identiﬁed a key relationship between areas
f dominant frequency and areas of fractionation in sheep.
he investigators were able to localize areas with regu-
ar, fast, spatiotemporally organized activity and map the
egions around them. Waves propagating from these areas
ere found to break and change direction recurrently at a
oundary zone, and demonstrate fractionation of local elec-
rograms. Their ﬁndings suggested that one of the possible
lectrophysiologic mechanisms for AF relating to the hypoth-
sis that high-frequency reentry at the boundary zones is
esponsible for the fractionation.
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Figure 2 Six cardiac ganglionic plexi (GP) are located on or near the left and right atria and have been shown to exhibit inﬂuence
on the initiation and perpetuation of AF: superior left atrial GP, posterolateral left atrial GP, posteromedial left atrial GP, left anterior
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oronary sinus; LOM, Ligament of Marshall; SVC, superior vena ca
ein; RSPV, right superior pulmonary vein; RIPV, right inferior p
The most prominent theory underlying the occurrence of
FAE involves the complex interplay of the intrinsic cardiac
ervous system on atrial tissues. The cardiac ganglionic
lexi (GP) are a collection of autonomic nervous tissues with
fferent and efferent sympathetic and parasympathetic
bers [20—23]. Six major GPs that may exert inﬂuence on
he atria (Fig. 2) are:
. Superior LA.
. Posterolateral LA.
. Posteromedial LA.
. Anterior descending.
. Posterior RA.
. Superior RA.
n animal models, the stimulation of parasympathetic ﬁbers
ithin the GP has been shown to decrease atrial effective
efractory periods and allow AF to perpetuate [24]. Simulta-
eously, stimulation of sympathetic ﬁbers may occur in sim-
lar areas, which can initiate PV ectopy [25]. Unfortunately,
apping and ablating the GP is time consuming and difﬁcult.
Ongoing research has identiﬁed a close relationship
etween the location of CFAE and the GP in animal models
24—26]. CFAE-targeted ablation may provide a surrogate for
odiﬁcation of the GP if this relationship can be conﬁrmed
w
i
r
e. LAA, left atrial appendage; RAA, right atrial appendage; CS,
SPV, left superior pulmonary vein; LIPV, left inferior pulmonary
nary vein (adapted from [20,21]).
n humans. Certainly, ablation in areas that have resulted in
vagal response has shown excellent results in the treat-
ent of AF [26].
egional distribution of CFAE
ach individual has temporal and special stability of
FAE, which facilitates accurate mapping. These regions
re not symmetrically located within the atria, but can
e predictably sought in certain places during mapping
10,23,27]. The following key areas have demonstrated a
redominance of CFAE within our cohort: (1) the proximal
oronary sinus; (2) superior vena cava—RA junction; (3)
eptal wall anterior to the right superior and inferior PVs;
4) anterior wall medial to the LA appendage; (5) area
etween the LA appendage and left superior PV; and (6)
osterosuperior wall medial to the left superior PV (Fig. 3).
ypically, patients with persistent or long-lasting AF have
reater numbers and locations of sites with CFAE than those
ith paroxysmal AF [10].
The distribution of CFAEs in the right and left atria
s vastly different from one area to another. Despite
egional differences in the distribution of these atrial
lectrograms, CFAEs are surprisingly stationary, exhibiting
Catheter ablation of atrial ﬁbrillation 5
Figure 3 The most common locations of complex fractionated atrial electrograms are identiﬁed (darkest shading) on a grid
representing the regions of the right and left atria. LA, left atrium; LAA, left atrial appendage; RA, right atrium; CS, coronary
sinus; FO, fossa ovalis; LSPV, left superior pulmonary vein; LIPV, left inferior pulmonary vein; RSPV, right superior pulmonary vein;
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tRIPV, right inferior pulmonary vein. The ablation catheter (ABL
electrograms can be seen in this example to exist on the LA sept
local electrograms at the RSPV antrum are less fractionated, bu
relatively spatial and temporal stability. Thus, one can
perform point-to-point mapping of these CFAE areas and
associate them into an electroanatomical map.
CFAE mapping
Mapping is always performed during AF by point-to-point
mapping, although detailed mapping of the LA, coronary
sinus, and occasionally RA is required. The spatial and tem-
poral stability of CFAE allows the precise localization of
these electrograms.
In our institution, we usually create a map with a min-
imum of 100 data points, especially in high-density areas
commonly known to have CFAE. Additionally, we usually
create a detailed map of the proximal coronary sinus, and
occasionally the RA. We identify locations with stable elec-
trograms, and these are ‘‘tagged’’ to create targets for
ablation. Areas with ﬂeeting CFAE are not sought as a pri-
mary target. A highly reliable map allows for minimal use
of ﬂuoroscopy. We routinely use less than 10min during an
average procedure duration of 113—27min.
Recently, we developed and tested a customized soft-
ware package to assist in the process of mapping (CFAE
software module, CARTO, Biosense-Webster, Diamond Bar,
CA, USA) [11]. The software analyzes data on atrial elec-
trograms collected from the ablation catheter over a 2.5-s
recording window and interprets it according to two vari-
ables: (1) shortest complex interval (SCL) minus the shortest
interval found (in milliseconds), out of all intervals identi-
w
B
a
e
sused to map and ablate the CFAE. The most highly fractionated
ll, although they still exist in the CS ostia and LIPV antrum. The
e a very short cycle length, and this may represent a ‘‘driver.’’
ed between consecutive CFAE complexes; and (2) interval
onﬁdence level (ICL) minus the number of intervals iden-
iﬁed between consecutive complexes identiﬁed as CFAE,
here the assumption is that the more complex inter-
als that are recorded—–that is, the more repetitions in a
iven time duration—–the more conﬁdent the categorization
f CFAE. Information from these variables is projected on
three-dimensional electroanatomic shell according to a
olor-coded scale. This allows targeting and retargeting of
reas of signiﬁcant CFAE.
rocedural details
decapolar catheter is placed in the coronary sinus for
eference and pacing. A single transseptal puncture under
emodynamic and ﬂuoroscopic guidance is used to access
he LA. Patients who are not in AF at the onset of the pro-
edure undergo an aggressive induction protocol utilizing
urst pacing in the coronary sinus and atria at a lower limit
f 1:1 capture or cycle length of 170ms with additional
ntravenous isoproterenol (1—3mcg/min) as required. AF is
onsidered stable for mapping if it can be sustained for more
han 60 s.
We use an open-irrigation 3.5-mm-tip ablation catheter
ith a large or extra-large curve (Thermacool F or J,
iosense-Webster) irrigating at 30ml/min during lesion cre-
tion. Power settings are 35—50W throughout the atria
xcept for the posterior wall (15—30W) and coronary
inus (10—25W). Careful power titration is required during
6 K. Nademanee et al.
Figure 4 (A) An example of electroanatomical maps from a patient (PO) who had chronic persistent atrial ﬁbrillation (AF) with
severe left ventricular dysfunction and chronic heart failure. The patient also had a previous atrioventricular nodal ablation and
implantation of a cardioverter deﬁbrillator. The map shows the 2 views (LAO and PA) [LAO= left anterior oblique; PA = posteroanterior]
of mesh-voltage maps of both atria and the coronary sinus. The maps display ablation points (red dots) over the antrum of the
left superior pulmonary vein (LSPV), the right superior and inferior pulmonary veins (RSPV and RIPV), septum, lateral aspect of mitral
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ECatheter ablation of atrial ﬁbrillation
radiofrequency (RF) to ensure complete lesion creation. RF
duration is usually 10—60 s and is halted because of patient
discomfort or elimination of CFAE. Because of occasional
noise on the ablation catheter during RF, multiple short
(15—30-s) applications may be used.
One of the most important aspects of CFAE ablation (and
one of the most common challenges early in the learning
curve of this technique) is to revisit areas that were initially
ablated to ensure that there has been no recovery of electri-
cal activity. If the patient remains in AF despite elimination
of all visible CFAE, intravenous ibutilide (1mg over 10min;
may repeat once to a maximum of 2mg) is used to increase
the cycle length of the arrhythmia in ‘‘non-driver’’ atrial
tissue and thus highlight the remaining areas of greatest
signiﬁcance (e.g. CFAE associated with perpetuating AF).
Alternatively, an intravenous dose of procainamide at
1000mg given as 20mg/min may be used. Often during CFAE-
targeted AF ablation, the arrhythmia evolves into an atrial
tachyarrhythmia (AT). Using the CS catheter as a reference,
the AT is subsequently mapped and ablated. Most often the
sites of origin of the AT are at the same locations as the
CFAE, which were targeted during the initial part of the pro-
cedure. The endpoints employed are either: (1) termination
of AF (and if the presenting rhythm was paroxysmal AF, it
must not be re-inducible); or (2) elimination of all CFAE.
Occasionally, a patient will remain in AF or AT after an
extensive ablation eliminating all CFAE, and despite the use
of ibutilide. In this small group of patients, an external car-
dioversion is required. Fig. 4 shows examples of our map
from a patient who had persistent AF and severe LV dysfunc-
tion; the patient had previous atrioventricular (AV) nodal
ablation with an implantable cardioverter deﬁbrillator. After
the ablation, atrial ﬁbrillation burden was reduced to zero
percent as shown in Fig. 4C; maintaining SR in this patient
improved ejection fraction from 21% before the ablation to
54%.
Evidence that CFAE areas represent AF substrates
Our recent study results support the hypothesis that CFAE
areas are critical in perpetuating AF and RF ablations over
these areas, resulting in the termination of AF and rendering
the atria no longer able to sustain AF [10]. The ﬁndings are
summarized as follows.
The study population included 121 patients (29 females;
mean age, 63 years) with refractory AF (57 paroxysmal,
64 chronic). All patients underwent non-ﬂuoroscopic elec-
troanatomic mapping (CARTO) during AF. Using CARTO, the
bi-atrial replica, displayed in a 3D color-coded voltage map,
was created during AF, and areas associated with CFAEs were
identiﬁed.
RF ablation of the area with CFAEs was performed to the
closest anatomic barrier. We found CFAE in seven different
A
w
A
w
annulus and the coronary sinus OS; cavo-tricuspid isthmus was also
show representative electrograms over the areas pointed by the arr
the pulmonary veins were low voltage complex fractionated atrial e
also showed fast atrial electrograms (<120ms) compared to the rest
of years as shown in (C). (C) A cardiac compass of AF burden from
recurrent AF. (For interpretation of the references to color in the ﬁ
article.)7
egions, but mainly conﬁned to the interatrial septum, PVs,
oof of LA, and left posteroseptal mitral annulus and coro-
ary sinus ostium. Ablations of the areas associated with
FAEs resulted in termination of AF without external car-
ioversion in 115 of the 121 patients (95%); 32 (28%) required
oncomitant ibutilide treatment. At 1-year follow-up, 110
91%) patients were free of arrhythmia and symptoms, 92
fter one ablation (76%), and 18 after two.
In virtually all patients, after RF applications over
he CFAE areas, most atrial electrograms either disap-
eared or were reduced drastically in amplitude, resulting
n complete elimination of CFAEs, often associated with
rganization of atrial electrograms in the areas adjacent
o the ablated ones. The elimination of CFAEs always
niformly increased tachycardia cycle lengths before AF
ermination, even though the cycle lengths were mea-
ured from the electrical reference of the area remote
rom the ablation sites. The overall tachycardia cycle
ength increased from 172± 26ms at baseline to 237± 42ms
p < 0.05).
Clearly, the preceding ﬁndings suggest that CFAE areas
re indeed the substrates that perpetuate AF. These ﬁnd-
ngs also demonstrate that our ablation approach is very
ffective and yields excellent long-term outcomes; thus, by
limination of CFAE areas, the substrate is also removed and
he atria can no longer ﬁbrillate.
ong-term clinical outcomes
e recently expanded the preceding ﬁndings by studying 540
igh-risk patients with both paroxysmal and chronic AF, who
nderwent catheter ablations for AF. Twenty-six patients
ere lost to follow-up [18].
After the follow-up period of 839± 493 days, 445 of the
14 patients remained in normal sinus rhythm (NSR) (87%);
he remaining 69 patients continued to have ATs (parox-
smal AF in 16, persistent AF in 17, permanent AF in 34,
nd atypical atrial ﬂutter in 2 patients). AF ablations were
igniﬁcantly more effective in maintaining sinus rhythm in
atients with paroxysmal AF (93%; 208 of 224 patients)
nd persistent AF (87%; 99 of 114 patients) compared to
hose with permanent AF (78%; 138 of 176 patients). Of
hese 445 patients who remained in sinus rhythm, only 59
atients (11%) were taking antiarrhythmic agents: 43 oral
miodarone and 16 sotalol.
ffects of maintaining sinus rhythm on mortalitys shown in Fig. 5, maintaining sinus rhythm was associated
ith a much better survival rate compared to those whose
F ablation failed to restore sinus rhythm (p < 0.0001). There
ere 20 deaths; 11 of the 445 patients (2.5%; 3 cardiac and 8
ablated. Ablation over these areas terminated AF (B). Insets
ows. Note that atrial electrograms over the left the antrum of
lectrograms. Cavo-tricuspid isthmus areas of the right atrium
of the right atrium. The patient had been AF free for a couple
the patient of Fig. 1. After the ablation, the patient had no
gure caption, the reader is referred to the web version of the
8 K. Nademanee et al.
Figure 5 Kaplan—Meier curve demonstrating improved sur-
vival in patients who remained in normal sinus rhythm (NSR)
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Figure 7 Multiple overlay Kaplan—Meier survival curves
among 4 strata of patients: (1) patients with ejection frac-
tion (EF) > 40% and normal sinus rhythm (orange), (2) patients
with EF < 40% and normal sinus rhythm (green), (3) patients with
EF > 40% and atrial ﬁbrillation (purple), and (4) patients with
EF < 40% and atrial ﬁbrillation (blue). (For interpretation of the
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arom all-cause mortality compared with patients who remained
n atrial ﬁbrillation (AF).
oncardiac deaths) who remained in NSR died compared to
of the 69 patients (13%; most were cardiac deaths) whose
blation failed to restore sinus rhythm during the follow-up
eriod.
Multivariate analysis showed that sinus rhythm was
n independent factor for survival (hazard ratio 0.085;
< 0.0001), whereas AF was a dependent risk of death (haz-
rd ratio 11.8; p < 0.0001).
History of congestive heart failure, but not EF, was also
n independent risk of death (hazard ratio 6.3; p = 0.0004).ffects of maintaining sinus rhythm on EF
here were 124 patients who had a depressed EF (≤40%), of
hese 124 patients, 101 patients were in NSR. EF signiﬁcantly
mproved after 6 months of being in NSR in a signiﬁcant
E
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r
igure 6 Comparison of individual changes in ejection fraction b
blation vs. atrial ﬁbrillation patients after ablation. Pre = pre-ablateferences to color in the ﬁgure caption, the reader is referred
o the web version of the article.)
umber of patients (Fig. 6); the EF increased from 31± 6%
o 41± 12% (p < 0.001). In contrast, there were no changes
n EF in the 23 patients who failed to respond to AF abla-
ions and remained in AF (pre-ablation EF was 24± 8% and
ost-ablation EF was 23± 8%).
Fig. 7 shows the Kaplan—Meier survival curves compar-
ng four strata: Patients in sinus rhythm with an EF≤ 40%;
atients in sinus rhythm with EF > 40%; patients in AF with
F≤ 40%; and patients in AF with EF > 40%. Clearly, patients
n AF with an EF < 40% have the worst prognosis. Interest-
ngly, patients with an EF > 40%, but who remained in AF had
lower survival rate compared to patients in sinus rhythm
egardless of the EF.
efore and after ablation: normal sinus rhythm patients after
ion and Post = 6—12 months post-ablation.
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Relation between discontinuation of
anticoagulation therapy and bleeding, stroke, and
embolic incidence
Anticoagulation (AC) therapy was discontinued in 392
patients (76%). Seven patients experienced a major stroke
or transient ischemic attack (TIA): 3 patients whose AC ther-
apy was stopped developed a serious stroke and 1 patient
had a TIA (1%) compared to 3 patients (2.7%) in the group
with continued AC treatment; 2 were ischemic strokes and 1
involved central nervous system bleeding leading to patient
death.
Thus, the AC group had a higher rate of events (death,
bleeding, stroke) compared to the no-AC group, largely due
to the higher death rate in the AC group since the majority
of the anticoagulated patients continued to have AF.
Procedure complications
Five patients suffered from a cerebrovascular accident (CVA)
(0.9%); incidentally, in 2 of the 5 patients, CVA occurred
24—48 h after the procedure. Hemopericardium occurred in
7 patients (1.4%), 1 of which required cardiovascular sur-
gical repair of the perforation of the LA at the ablation
site; the remaining 6 patients were treated successfully with
pericardiocentesis. Nine patients developed major vascu-
lar complications at the groin sites (7 pseudoaneurysm; 2
AV ﬁstula). Two patients developed AV block and required
permanent pacemaker implantation. Three patients had
transient pulmonary edema after the procedure.
There were no procedure-related deaths. However, two
patients died within 30 days of the procedures. One of the
preceding patients who developed a serious stroke 2 days
after the procedure died from a stroke 3 weeks later, and the
other patient died from respiratory failure from her chronic
obstructive pulmonary disease complicated with infection.
Other studies
Our introduction of CFAE mapping to guide AF ablation, as an
alternative to anatomical approach of PVI, either alone for
PAF or with linear lesions for chronic AF, spurred other inves-
tigators to follow our approach. Unfortunately, our results
were not fully reproduced by others [28,29]. Oral et al.
mapped CFAE as target sites for AF substrate in patients
with chronic AF [28]. Of the 100 patients in this study, only
12 (12%) patients had AF converted to sinus rhythm during
the ablation and 4 (4%) converted to atrial ﬂutter. After ibu-
tilide treatment, 27more patients converted to sinus rhythm
and 13 to atrial ﬂutter. There were 44 patients (44%) who
remained in AF and were converted to SR by external car-
dioversion. The low acute AF termination rate in the Oral
et al. study also rendered a high rate of AF or atrial tach-
yarrhythmia recurrences: only 33% of their patients were in
SR without any antiarrhythmic drug after single procedure
(mean follow-up of 14± 7 months) and 57% of the patients
were in SR after the second procedure. However, our sub-
sequent experience in 410 persistent AF who underwent AF
ablation guided by CFAE mapping conﬁrmed our initial obser-
vation and in contrast with Oral’s study [18,30,34]. We were
A
a
R
a9
ble to terminate atrial ﬁbrillation in 80% of the patients
including using ibutilide). Of the 410 high-risk patients in
ur study, 81% were in SR without any antiarrhythmic drug
ncluding the second procedure.
While it is unclear what exactly are the factors underly-
ng the differences in both acute and long-term outcomes
etween the two studies, it seems more likely that one
r more of the following key variables may help explain
he differences between the 2 studies [30]: (1) Right atrial
blation: Oral and co-workers, in the above study, did not
ap and ablate the right atrium. We found that 15% of our
atients required right atrial ablation; the common sites
re right postero-septum, cavo-tricuspid isthmus, tricus-
id annulus, and rarely posterior wall of the right atrium
nd SVC-right atrial junction. (2) Power and duration of
F energy applications: our power of RF applications is
igniﬁcantly higher than those of Oral et al. (3) Ablation
ndpoint: perhaps this variable is the most signiﬁcant fac-
or inﬂuencing the differences in the two studies. We believe
hat CFAE are low voltage atrial signals usually ranging
rom 0.05—0.25mV and the areas with the very low volt-
ge signals (between 0.05 and 0.1mV) are often the most
esirable. By contrast, Oral and co-workers deﬁned suc-
essful lesion creation as a voltage reduction to <0.1mV
r by decreased by ≤80% reduction. This single factor may
xplain why the investigators did not have a high success
ate of acute termination. In our experience, the ablation
ites where AF terminated are often the sites that we had
pplied RF before and often the voltage of atrial signals
t these successful sites were in the range of 0.5—0.8mV.
4) Procedure endpoint: the procedure endpoint in the Oral
tudy and our study is also different. After elimination of
FAE sites ablations, we deliberately attempt to ablate all
‘new’’ arrhythmias including pleomorphic forms of atrial
achyarrhythmias whereas Oral and colleagues did not. Fur-
hermore, we did not use ibutilide solely for converting the
rrhythmias to sinus rhythm but rather as an aid to assist in
apping the tachycardia after CFAE ablations. My colleagues
nd I share the same experiences as Oral et al. in that ibu-
ilide rarely converts the arrhythmias to SR. However, the
rug is invaluable in helping identify sites that continue to
e the source of tachyarrhythmias by further lengthening
he tachycardia cycle length and removing the pleomorphic
orm of the tachycardia or making the tachycardia more sta-
le. Again, often after ibutilide, we found that we had to go
ack to the areas that we had previously ablated and had to
eapply RF applications to terminate tachycardia. CFAE map-
ing in the left atrium requires a deliberate and painstaking
ffort to explore all areas of the atria. (5) Comprehensive
apping: lastly, the electroanatomic map for CFAE should
ave high density of evenly spread mapping points. It was
nclear whether other investigators committed to detailed
apping of the CFAE; but there is no question that the key
o the success of AF ablation guided by CFAE must have all
reas of the atria and coronary sinus explored.blation of CFAE as an adjuvant to PVI and linear
blations
ecently, ablation of CFAE areas during AF has been
dopted as part of a hybrid approach for AF ablation, espe-
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ially for non-paroxysmal AF since PVI alone is not highly
ffective in the majority of patients with long-lasting per-
istent AF. Thus, many investigators continue to search
or a better technique for AF treatment for this subset.
any centers presently incorporate CFAE ablation as an
djuvant to their approach [31—34]. Using PVI as a cor-
erstone of their AF ablation, many investigators added
FAE ablations in their strategies with variable successes.
able 1 summarizes the results of the recent published
ata which revealed that the long-term success rate after
hybrid approach of combining PVI plus CFAE ablation
nd linear lesions at some institutions yielded a better
uccess rate than PVI alone in patients with persistent
F.
For patients with PAF, Porter et al. performed ablation
nitially targeting CFAE and resulting in AF termination in
8% of the patients and the investigators then proceeded
o perform PVI yielding 90% long-term success in these PAF
atients after a single procedure [17]. These results are
uite impressive and clearly suggest further evaluations of
he role of a combined PVI and CFAE ablations in treating AF
atients.
onclusions
n conclusion, data from the technique of substrate abla-
ion guided by CFAE mapping, in contrast with previous
tudies in AF ablation that included largely a young parox-
smal AF population, show greater beneﬁts to the elderly
nd high-risk populations with structural heart disease.
learly, more studies are needed before recommending
atheter ablation as the ﬁrst-line therapy for all high-risk
F patients. In the meantime, our research demonstrates
hat the catheter-based ablative approach is a promis-
ng modality for many symptomatic AF patients, and has
reat potential to become the mainstay for AF treat-
ent.
Finally, one must recognize that AF ablation, regard-
ess of the technique used, is a challenging task that
equires operator skills in manipulating catheters in
he atrial chambers, understanding all facets of clin-
cal electrophysiology, early recognition, and treating
rocedure-related complications. Many of these skills can
e achieved with proper training and hands-on experience
fter exposure to an adequate number of the proce-
ures.
Advances in technologies and development of new
ools such as robotic navigation of catheters, which are
eing introduced at an impressive pace, will undoubt-
dly help electrophysiologists to become more proﬁcient
o the task. Similarly, it is imperative that the AF
blation procedures be done in centers that are well-
quipped with an advanced electrophysiology mapping
ystem and ancillary equipment, along with an expe-
ienced team, to ensure the best possible patient
utcomes.cknowledgments
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emorial Hospital and Seven Day Adventist Foundation.
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